NCT01195636

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Systemic Exposure of Topical XPF-002 in Subjects With Postherpetic Neuralgia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Xenon Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia

Conditions

• Postherpetic Neuralgia

Interventions

Type	Name	Description
DRUG	XPF-002	Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
DRUG	Placebo	Twice daily application of Placebo ointment

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-09-06
• Last updated: 2013-11-25
• Results posted: 2013-11-25

Locations

24 sites across 1 country: United States